In this issue:
- Polatuzumab vedotin in previously untreated DLBCL
- Second-line CAR T-cells in B-cell lymphoma
- Predicting CAR T-cell-related haematological toxicity in relapsed/refractory large B-cell lymphoma
- 5-year results from ECHELON-2: brentuximab vedotin + CHP for CD30+ PTCL
- Pembrolizumab + rituximab in relapsed/refractory follicular lymphoma
- Tisagenlecleucel in relapsed/refractory extramedullary ALL
- Axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma
- SCT after CD19-CAR T-cellinduced ALL remission improves LFS
- Ciltacabtagene autoleucel vs. physician’s choice in relapsed/refractory MM
Download PDF